Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

A letter to The Lancet in 1982 reported that "we have previously shown that there is a high incidence of chronic liver disease among patients receiving blood product concentrates even in the absence of any symptoms."

  • Read more about A letter to The Lancet in 1982 reported that "we have previously shown that there is a high incidence of chronic liver disease among patients receiving blood product concentrates even in the absence of any symptoms."

The results of a survey between Sheffield and the Royal Free on chronic hepatitis showed that approximately one third of the patients studied had the appearance of chronic active (aggressive) hepatitis.

  • Read more about The results of a survey between Sheffield and the Royal Free on chronic hepatitis showed that approximately one third of the patients studied had the appearance of chronic active (aggressive) hepatitis.

It was the view of the reference centre directors at the special meeting on 13 May 1983 that cryoprecipitate was not particularly easy to use as there was no guarantee of the amount of Factor 8 in each bag, and it was not a particularly useful therapeutic option for major surgery or major bleeds.

  • Read more about It was the view of the reference centre directors at the special meeting on 13 May 1983 that cryoprecipitate was not particularly easy to use as there was no guarantee of the amount of Factor 8 in each bag, and it was not a particularly useful therapeutic option for major surgery or major bleeds.

Dr Preston's approach to purchasing a number of different commercial concentrates was "not putting all the eggs in one basket in case something happened with the supply chain..." and "keep individual patients on the same concentrate, and the same 'batch' for as long as possible to minimise exposure to different blood donations."

  • Read more about Dr Preston's approach to purchasing a number of different commercial concentrates was "not putting all the eggs in one basket in case something happened with the supply chain..." and "keep individual patients on the same concentrate, and the same 'batch' for as long as possible to minimise exposure to different blood donations."

Dr preston's view was that the amount of Factor 8 (and Factor 9) given to patients was very much less than the majority of other reference centres.

  • Read more about Dr preston's view was that the amount of Factor 8 (and Factor 9) given to patients was very much less than the majority of other reference centres.

Dr Preston does not recall telling patients that the treatment they were receiving might expose them to the risk of chronic liver disease.

  • Read more about Dr Preston does not recall telling patients that the treatment they were receiving might expose them to the risk of chronic liver disease.

Dr Preston confirmed that part of his approach to patients was to "keep individual patients on the same concentrate, and the same 'batch' for as long as possible to minimise exposure to different blood donations"

  • Read more about Dr Preston confirmed that part of his approach to patients was to "keep individual patients on the same concentrate, and the same 'batch' for as long as possible to minimise exposure to different blood donations"

Dr Preston stated in his evidence to the Inquiry that whilst the hepatitis risk from commercial products was substantially greater than from NHS products, "there were insufficient NHS products for the treatment of Royal Hallamshire Hospital patients".

  • Read more about Dr Preston stated in his evidence to the Inquiry that whilst the hepatitis risk from commercial products was substantially greater than from NHS products, "there were insufficient NHS products for the treatment of Royal Hallamshire Hospital patients".

Dr Preston's policy was to treat people with mild haemophilia with DDAVP as soon as it became available.

  • Read more about Dr Preston's policy was to treat people with mild haemophilia with DDAVP as soon as it became available.

A survey between Sheffield and the Royal Free showed that approximately one third of the patients studied had the appearance of chronic active (aggressive) hepatitis.

  • Read more about A survey between Sheffield and the Royal Free showed that approximately one third of the patients studied had the appearance of chronic active (aggressive) hepatitis.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 63
  • Page 64
  • Page 65
  • Page 66
  • Current page 67
  • Page 68
  • Page 69
  • Page 70
  • Page 71
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.